Allogene Therapeutics, Inc. - 8-K Filing
Allogene Therapeutics reports Q3 2026 net loss of $50.4 million and maintains $388.9 million in liquidity.
Tickers: $ALLO
More Regulatory news
- OLD NATIONAL BANCORP /IN/ - 8-K Filing
- AMTECH SYSTEMS INC - 8-K Filing
- REGIONAL HEALTH PROPERTIES, INC - 8-K Filing
- Bitwise Avalanche ETF - 8-K Filing
- MiNK Therapeutics, Inc. - 10-Q Filing
- Future Vision II Acquisition Corp. - 10-Q Filing
- THUNDER MOUNTAIN GOLD INC - 10-Q Filing
- MiNK Therapeutics, Inc. - 8-K Filing
- SusGlobal Energy Corp. - 10-Q Filing
- Ideal Power Inc. - 8-K Filing